

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Ab&B Bio-Tech CO., LTD. JS

江蘇中慧元通生物科技股份有限公司

(A joint stock company established in the People's Republic of China with limited liability)

(Stock Code: 2627)

VOLUNTARY ANNOUNCEMENT IND APPROVAL BY CHINA CDE FOR MRNA MPOX VACCINE

This announcement is made by Ab&B Bio-Tech CO., LTD. JS (the “**Company**” or “**Ab&B Bio-Tech**”, together with its subsidiary, the “**Group**”) on a voluntary basis to inform the shareholders of the Company and potential investors about the latest business advancement of the Group.

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company is pleased to announce that following its Investigational New Drug (the “**IND**”) application in the United States (“**U. S.**”) being approved by the U.S. Food and Drug Administration (the “**FDA**”), the Center for Drug Evaluation of the National Medical Products Administration (the “**China CDE**”) has approved the IND application of the Group’s self-developed mRNA mpox vaccine candidate on June 21, 2026.

Mpox is caused by the mpox virus, a member of the orthopoxvirus genus in the poxvirus family. This genus comprises a wide group of viruses, including vaccinia virus, variola virus and ectromelia virus, among others. In preclinical studies, our mRNA mpox vaccine candidate elicited significantly higher neutralizing antibody levels against mpox compared to the live-attenuated variola virus vaccine (Tian Tan strain) used in China, and it exhibited broad-spectrum cross-reactivity against a variety of orthopoxvirus antigens. Compared to the approved replication-defective mpox vaccines abroad, the outstanding immunogenicity of our mRNA mpox vaccine candidate provides a more suitable option for immunocompromised individuals (such as those who are HIV-positive). This was the world’s first mRNA mpox vaccine candidate to receive IND approval by both the FDA and the China CDE.

About Ab&B Bio-Tech

Ab&B Bio-Tech is a China-based vaccine company dedicated to the research, development, manufacturing and commercialization of innovative vaccines and traditional vaccines adopting new technical methods. In formulating our pipeline, we closely track global trends in infectious disease incidence and vaccine R&D, with a strategic focus on premium vaccines, aiming to replace traditional vaccines and imported vaccines in China and establish our presence in international markets. Our range of products include but are not limited to, the quadrivalent subunit influenza vaccine, the trivalent subunit influenza vaccine and lyophilized human rabies vaccine candidate, along with other vaccine candidates.

Continued Suspension of Trading

Trading in the H Shares of the Company on The Stock Exchange of Hong Kong Limited has been suspended with effect from 9:00 a.m. on Wednesday, April 1, 2026 and will remain suspended until further notice.

Further announcement(s) will be made by the Company to keep the Shareholders and potential investors informed of any material development in this regard as and when appropriate.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
Ab&B Bio-Tech CO., LTD. JS
Mr. AN Youcai

Executive Director, chairman of our Board and general manager

Hong Kong, June 23, 2026

As at the date of this announcement, the Board comprises: (i) Mr. AN Youcai, Ms. LI Runxiang and Mr. HE Yiming as executive Directors; (ii) Mr. YU Jianlin and Mr. DU Mu as non-executive Directors; and (iii) Mr. LI Xiangming, Mr. LI Jianjun, Mr. CHEN Chengbei and Ms. LUI Mei Ka as independent non-executive Directors.